Is this your firm? Get featured or correct your listing →
Recent changes
- Oct 13, 2026Oct 13, 2026Invested in Souffle Therapeutics (Series B, $135M) FinancialContent
- Sep 22, 2026Sep 22, 2026New fund: Vida Ventures Fund IV (target $500M) SEC EDGAR Form D
Funds
1| Fund | Vintage | Size | Strategy | Source |
|---|---|---|---|---|
| Vida Ventures Fund IV | 2026 | target $500M | Flagship | As of Sep 22, 2026SEC EDGAR Form D |
Portfolio
1 totalRecent Investment Activity
1Track record: led 0 and participated in 1 of 1 tracked venture round · 1 in the last 12 months
| Date | Company | Event | Role | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|---|---|
| Oct 13, 2026 | Souffle Therapeutics | Series B | Participated | $135M | — | Fidelity InvestmentsunverifiedARCH Venture PartnersunverifiedBessemer Venture PartnersunverifiedJanus Henderson InvestorsunverifiedLeaps by BayerunverifiedPolaris PartnersunverifiedTemasekunverifiedVida VenturesunverifiedJuvia GroupTCG Crossover ManagementBB BiotechBalyasny Asset Management+5 more | FinancialContent |
Co-Investors
7Similar Firms
overlapping sector, stage or regionLatest Pulse
- Oct 13, 2026Souffle Therapeutics Raises $135M For RNA TherapiesSouffle Therapeutics closed an oversubscribed $135 million Series B led by Juvia Group on Oct. 13 to push its RNA-delivery platform's first three programs toward the clinic.→
- Jun 10, 2026SonoThera Raises $125M for Ultrasound Gene TherapySonoThera closed an oversubscribed $125 million Series B led by Vida Ventures to push its ultrasound-delivered, nonviral genetic medicine platform toward its first clinical trial in Duchenne muscular dystrophy in 2027.→
Vida Ventures FAQ
What companies has Vida Ventures invested in?
Vida Ventures' portfolio includes Souffle Therapeutics.
Who does Vida Ventures co-invest with most?
In the rounds Value Add tracks, Vida Ventures most often invests alongside ARCH Venture Partners (1 shared deal), Bessemer Venture Partners (1 shared deal), Fidelity Investments (1 shared deal), Janus Henderson Investors (1 shared deal), Leaps by Bayer (1 shared deal).
Sources & methodologyshow
Where these figures come from
- SEC EDGAR Form Dprimary source1 fact
- FinancialContentresearch database1 fact
Figures are labelled Reported (a source states it), Estimated, Derived (computed from other facts) or Rumored (in talks / unconfirmed). Rumors never replace a confirmed figure. Each figure keeps its own as-of date; history is preserved rather than overwritten.